CN110368385A - Purposes of the indole -3-formaldehyde in preparation treatment atopic dermatitis drug - Google Patents
Purposes of the indole -3-formaldehyde in preparation treatment atopic dermatitis drug Download PDFInfo
- Publication number
- CN110368385A CN110368385A CN201910061852.4A CN201910061852A CN110368385A CN 110368385 A CN110368385 A CN 110368385A CN 201910061852 A CN201910061852 A CN 201910061852A CN 110368385 A CN110368385 A CN 110368385A
- Authority
- CN
- China
- Prior art keywords
- drug
- indole
- formaldehyde
- atopic dermatitis
- iaid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to pharmaceutical technology fields, it is related to the medicinal and skin care item purposes that tryptophan metabolite includes indole -3-formaldehyde (IAId) etc., and in particular to tryptophan metabolite includes purposes of the indole -3-formaldehyde in the drug and skin care item that preparation has immunoregulation effect；Our experiments show that AD sample inflammation and psoriasiform inflammation that the tryptophan metabolites such as described IAId can inhibit MC903 to induce, inhibit CD4 in corium+,Gr1+The infiltration of positive cell；Inhibit the expression of inflammatory factor；Reduce the degree that skin is lost through the severe edema due to hypofunction of the spleen；Mouse is inhibited to scratch behavior；Experimental result confirms that the tryptophan metabolites such as the IAId have the function of clearly anti-AD sample inflammation, it can be used for preparing the drug and skin care item for preventing and treating atopic dermatitis (eczema), it is especially formed into external preparation, for preventing and treating Acute and chronic inflammation caused by abnormal immune reaction.The prevention and treatment that the present invention is atopic dermatitis in the clinical application of clinical experimental stage sum provide new medicament selection, have extensive commercial applications prospect.
Description
Technical field
The invention belongs to pharmaceutical technology fields, are related to the new biological action of tryptophan metabolite, and in particular to tryptophan
Metabolite includes the medicinal and skin care item purposes of indole -3-formaldehyde (IAId) etc. more particularly to tryptophan metabolite includes
Purposes of the indole -3-formaldehyde in the drug and skin care item that preparation has immunoregulation effect；The tryptophan metabolite
Have the function of inhibiting immune response including indole -3-formaldehyde (IAId), is used especially for preparing external curing atopic dermatitis
The drug and skin care item of the inflammatory dermatoses such as (eczema), psoriasis.
Background technique
Data disclose atopic dermatitis (atopic dermatitis, AD) be the whole world most often include skin disease it
One, disease incidence increases year by year, and the disease incidence in children is up to 20% at present, according to statistics, about the children of a quarter at
Nian Houhui development is AD in adults, and about 1/5th AD infant makes further progress as the possibility of asthma.Since at present there is no thorough
The means that bottom cures, based on symptomatic treatment, medical practice show clinic, the illness state of an illness usually recurrent exerbation, acutely
The difficulty of social activity caused by itch, sleep disturbance and extensive skin lesion causes greatly to perplex to patient's physical and mental health, separately there is research table
Bright, the illness rate of depression, anxiety disorder and self-closing disease increases year by year in AD patient, and the social concern thus caused is more and more tighter
High, for AD patient while body and mind bears immense pressure, family and society need to put into a large amount of medical resource and health care expense
With causing high financial burden.It data show, be up to 5,000,000,000 beauty in the expense that the U.S. is dropped in every year on average on treatment AD
Member, the expense for treating AD account for the 10% of family income, cause huge financial burden to patient home and society.It grinds
Study carefully and disclose under the overall background that industrialization degree is constantly deepened and living condition greatly improves, the appearance of problem of environmental pollution with
And excessive cleaning habit is formed such that and also increases year by year in the disease incidence of China AD, causes greatly to patient, family, society
Burden.In the past few decades, although those skilled in the art have done wide research and discussion to the mechanism of AD, so far
Until still lack effective treatment means and precautionary measures.
Separately some researches show that skin flora imbalance is the important link of AD morbidity, wherein staphylococcus aureus abundance liter
The severity of high degree and AD is positively correlated, and all the time, inquires into skin flora and participates in the mechanism that AD is adjusted, pass through tune
The method of section flora treats and prevents the hot spot that AD is this field research, however previous research is directed generally to flora proper constituent
Effect study in AD, and related scholar thinks, information provided by opsonigenous substance has more functional meaning, and metabolism produces
Object can more reflect the information in terms of the vigor of flora, the functions such as pathogenic.In recent years, the flora and place that opsonigenous substance mediates
Main immune system interaction is receive more and more attention, will become the main target for the treatment of AD by the intervention of bacterial metabolism
Point, however, research focuses primarily upon therapeutic effect of the intestinal tract flora metabolite to bowl inflammatory diseases at present, so far, still
Have no the report of therapeutic effect of the skin flora metabolite to AD.
Tryptophan is the important sources of nitrogen source needed for flora is survived, and indoles and its derivative are a kind of important tryptophan generations
Thank product, the horizontal adjusting by related flora level；Indoles substance plays important in adjusting intraor extracellular signal path
Effect, it is considered to be link up the key substance between environment, flora and human body three.Indole -3-formaldehyde is a kind of important Yin
Diindyl class metabolite, some researches show that indole -3-formaldehydes, and the IL-22 of aryl hydrocarbon receptor (AhR) access can be relied on by promotion
Transcription, inhibit the field planting of Candida albicans in enteron aisle, maintain the balance of intestinal flora, inhibit intestinal inflammation, but not yet
See the research report of the adjustment effect in relation to indole -3-formaldehyde in AD inflammation.
Status based on the prior art, present inventor is quasi- to provide indole -3-formaldehyde (IAId) new medicinal and shield
The purposes of skin product purposes, especially indole -3-formaldehyde in the drug and skin care item that preparation has immunoregulation effect.
Summary of the invention
The purpose of the present invention is the statuses based on the prior art, provide tryptophan metabolite new biological action, relate to
And tryptophan metabolite includes the new medicinal and skin care item purposes such as indole -3-formaldehyde (IAId), and in particular to tryptophan generation
Thank purposes of the product indole -3-formaldehyde in the drug and skin care item that preparation has immunoregulation effect, especially tryptophan generation
Thank to purposes of the product indole -3-formaldehyde in the drug and skin care item that preparation inhibits inflammatory reaction, the tryptophan metabolism produces
Object indole -3-formaldehyde can be used for the inflammatory dermatoses such as external application prevention and treatment atopic dermatitis (eczema), psoriasis.
Tryptophan metabolite indole -3-formaldehyde (IAId) of the present invention is a kind of with structure shown in Fig. 7
Indole derivatives, research shows that a variety of tryptophan metabolites have similar biological action, such as IAA, TrA tryptophan
Metabolite.
In the present invention, the AD model (MC903 model) induced by the mouse Calcipotriol (MC903) of foundation is carried out
The tryptophan metabolites such as indole -3-formaldehyde inhibit the experiment of AD sample inflammation, the results show that
(1) inhibiting effect of the IAId to AD sample dermatitis
1) external preparation for skin IAId mitigates AD sample inflammation
It is continuous to smear 14 days in MC903 model mice ear external application IAId, the result shows that mouse AD sample is scorching after external application IAId
Disease is substantially reduced, substantially shows as the red and swollen mitigation of IAId group, the scales of skin that peel off reduces (as shown in Figure 1A)；HE dyeing display intradermal leaching
The inflammatory cell of profit reduces (as shown in Figure 2 B)；IAId group ear thickness is substantially reduced (as shown in Figure 1 C), in addition to this, passes through view
Frequency record discovery external application IAId can obviously inhibit the scratching behavior (as shown in figure iD, * * * P < 0.001) of mouse；
2) external application IAId can inhibit the expression of inflammatory factor, reduce the total IgE level of peripheral blood,
RT-PCR the results show that IAId obviously inhibit IL-4, IL-5, IL-6, IL-13, TSLP expression and
IAId inhibits the total IgE of peripheral blood horizontal (as shown in Fig. 2A~2F) to ELISA as the result is shown；
3) external application IAId can inhibit the infiltration of inflammatory cell,
After external application IAId, the GR1 that is infiltrated in experiment mice otic tissues+As shown in Figure 3, (* * * P < 0.001), CD4+
The quantity of (as shown in Figure 3D, * * * P < 0.001) cell is significantly reduced compared with MC903 group, and CD8+The infiltration quantity of cell has no
There is statistical difference (as shown in Figure 3 C).
(2) inhibiting effect of the tryptophan metabolites such as IAA, TrA to AD sample dermatitis and psoriasis
The present invention has also carried out other tryptophan metabolites such as IAA, TrA and has tested to the effect of mouse AD sample scytitis
Research, the results show that the scytitis of mouse is substantially reduced (such as Fig. 4 institute after described tryptophan metabolite IAA, TrA effect
Show), the inflammatory cell of HE dyeing display intradermal infiltration reduces (as shown in Fig. 3 B)；
The present invention acts on the mouse psoriasiform inflammation mould of the imiquimod induction of preparation using described IAA, TrA
Type, as the result is shown., IAA, TrA effect after, psoriasiform dermatitis substantially change it is substantially reduced, histocytology display infiltration
Inflammatory cell significantly reduces (as shown in Figure 5), and it is aobvious to show that described tryptophan metabolite IAA, TrA have psoriasis model
The effect of the inhibition inflammation of work.
(3) tryptophan metabolites such as IAId, IAA, TrA promote the maintenance of barrier function
Experiment display, IAId, IAA, TrA remarkably promote the table of mice skin tissue barrier relevant molecule such as Filaggrin
It reaches, reduces and lose horizontal (as shown in Figure 6) through the severe edema due to hypofunction of the spleen, show that tryptophan metabolite takes part in the adjusting of skin barrier function.
The tryptophan metabolites such as IAId of the invention inhibit AD inflammation and psoriasiform inflammation the experimental results showed that,
The AD sample inflammation that the tryptophan metabolites such as IAId can inhibit MC903 to induce inhibits CD4 in corium+,Gr1+Positive cell
Infiltration；Inhibit the expression of inflammatory factor (IL-4, IL-5, IL-6, IL-13, TSLP)；Reduce the degree that skin is lost through the severe edema due to hypofunction of the spleen；
Mouse is inhibited to scratch behavior；The wherein psoriasiform skin that tryptophan metabolite IAA, TrA can effectively inhibit imiquimod to induce
It is scorching；Experimental result confirms that the tryptophan metabolites such as described IAId have the work of clearly anti-AD sample inflammation and psoriasiform inflammation
With can be used for preparing the drug and skin care item for preventing and treating the inflammatory dermatoses such as AD, be further used for preventing and control
Treat Acute and chronic inflammation caused by abnormal immune reaction.
In the present invention, the drug and skin care item of the inflammatory dermatoses such as prevention and treatment atopic dermatitis of the IAId preparation can
External preparation, including but not limited to liniment or gel is made.
The invention has the following advantages that
The tryptophan metabolites side effect such as IAId of the present invention is minimum, and safety coefficient is very high, can obviously inhibit special
The inflammatory reaction of answering property dermatitis, psoriasis；IAId is suitable for being formed with explicitly inhibiting the pharmaceutical preparation of Th2 type inflammatory reaction,
Compound medicinal formulation is formed including external preparation is made, or with other medicines, or prevention and day of the skin care item for disease is made
Often nursing.
Test result research of the present invention confirms that the tryptophan metabolites such as IAId are inhibiting the effect in Th2 type inflammation,
Drug development for tryptophan metabolites such as IAId as treatment AD provides more detailed theoretical foundation and new Research Thinking；
The prevention for being AD in clinical experimental stage and further clinical application and treatment provide new medicament selection, have extensive
Commercial applications prospect.
Detailed description of the invention
Fig. 1 is that local skin external application IAId of the present invention inhibits AD sample inflammation photo, wherein
A: mouse ear substantially photo；B: mouse ear tissue HE slice dyeing；C: the variation line chart of mouse ear thickness；D:
Scratching number of the mouse within half an hour；* 0.001 vs.MC903 group of P < 0.05, * * P < 0.01, * * * P <.
Fig. 2 is that IAId inhibits the expression of inflammatory factor and reduces whole blood IgE level, wherein A-E is followed successively by IL-4, IL-
5, the mRNA relative expression quantity of IL-6, IL-13, TSLP；F: outside mouse
Total IgE is horizontal in all blood；* P < 0.05, * * P < 0.01, * * * P < 0.001vs.MC903 group.
Fig. 3 is that IAId inhibits cell infiltration result figure, wherein
A: the streaming figure of the inflammatory cell infiltrated in mouse ear tissue；B: the number of GR1+ cellular infiltration in mouse ear tissue
Amount；C: the quantity of CD8+ cellular infiltration in mouse ear tissue；D: the quantity of CD4+ cellular infiltration in mouse ear tissue；* P <
0.05, * * P < 0.01, * * * P < 0.001vs.MC903 group.
Fig. 4 is IAA, and TrA inhibits AD sample inflammatory consequences,
A: mouse ear photo；B: mouse ear tissue HE dyeing.
Fig. 5 is IAA, and TrA inhibits psoriasiform inflammatory consequences,
Mice Auricle Topical Imiquimod prepares psoriasis model, and auricle skin lesion prepares HE slice.
Fig. 6 is the maintenance situation that IAId, IAA, TrA participate in skin barrier function,
A:RT-PCR detects the expression of filaggrin in mouse tissue, and B: different disposal is to mouse skin through the severe edema due to hypofunction of the spleen
Lose the influence of (TEWL), N=5, the * * * vs.MC903 group of P < 0.001.
Fig. 7 is the structure chart of tryptophan metabolite indole -3-formaldehyde (IAId) of the present invention.
Specific embodiment
Embodiment 1
1) it prepares MC903 mouse model and IAId intervenes:
Testing mouse used is ICR female mice, and 4-8 weeks size is raised in SPF rank environment, and mouse feed is SPF
Rank；In Mice Auricle external application MC903, once a day, continuous 14 days；While the preparation of MC903 model, outside mouse ear
It is continuous to smear 14 days with IAId；
2) record scratching number:
(1) selection is in the state of peace and quiet, with the behavior of cameras record mouse；
(2) 30min video is randomly selected, the total scratching number of every group of mouse is calculated；
3) it the inflammatory cell of flow cytometer detection mouse ear tissue infiltration: prepares mouse ear tissue monocytes suspension: wherein wrapping
It includes: being shredded mouse ear tissue using the scissors of disinfection, tweezers；The otic tissues shredded, after 4 DEG C of centrifugations 2000rpm, 5min
Remove supernatant；It is poured into 6 orifice plates after the tissue of precipitating is shredded again, the pancreatin of 2ml 0.5% is added in 37 DEG C of insulating boxs
Digest 5min；The tissue of digestion is added serum and terminates, and is transferred in streaming pipe after the filtering of 200 mesh filter screens；To streaming Guan Zhongjia
Enter the resuspension of 1ml culture medium；10 μ L cell suspensions are drawn from every pipe, are added in cell counting board, carry out cell with microscope
It counts；4 DEG C, 1200rpm is centrifuged 5min, adjusts volume according to cell count, and adjusting every solencyte concentration is 106/mL；Streaming
Cell analysis: centrifugation 1200rpm, 5min；Supernatant is abandoned, antibody diluent is added, is resuspended, 1200rpm is centrifuged 5 min；The step
It need to repeat 2 times, to completely remove culture medium；Supernatant is abandoned, antibody diluent is added to 100 μ L, anti-cell membrane molecule stream is added
5 μ L of formula antibody, rear to be resuspended, 4 DEG C are protected from light incubation, 30min；Streaming antibody cleaning solution is added again, is centrifuged 1200rpm after mixing,
5min, the step need to repeat 2 times, to completely remove streaming antibody；About 5 μ L of streaming antibody is added, 4 DEG C of incubations, keep away after resuspension
Light 30min；Streaming antibody cleaning solution is added, 1200rpm, 5min are centrifuged after mixing；The step need to repeat 2 times, to remove completely
Remove streaming antibody；Supernatant is abandoned, about 300 μ L fixers are added, is resuspended, 4 DEG C of avoid light places, flow cytomery is carried out；
4) detection of mouse peripheral blood IgE: it is conventional to take eyeball of mouse blood, it is put into EP pipe；Whole blood sample is quiet under room temperature
1h or so is set, is precipitated to serum；Centrifugation: 12000rpm, 6min are sucked out serum and are put into another EP pipe；Coated elisa plate, overnight；
Add standard items: being marked with quasi- sample wells on enzyme mark IgE coating plate, sequentially adding the standard items 50ul of various concentration, (each concentration does 2
A parallel hole)；Sample-adding: set respectively blank well (sample and enzyme marking reagent is not added in blank control wells, remaining each step operation is identical), to
Test sample sample wells is first loaded 40 μ l of product in sample to be tested hole on enzyme mark coating plate, is then loaded 10 μ l of product Avidin again, and sample-adding will
Sample is added on ELISA Plate hole bottom, does not touch hole wall, shakes and mixes；It incubates: incubating 30 points with 37 DEG C of sealing plate film sealing plate postposition
Clock；With liquid: will be spare after 30 times of concentrated cleaning solutions, 30 times of distilled water dilutions；Washing: taking sealing plate film off, discard liquid, dries,
Cleaning solution is filled it up in every hole, is discarded after standing 30 seconds, is so repeated 5 times, pats dry；Enzyme: the examination of enzyme mark is added in every hole in addition to blank well
50 μ l of agent；It incubates: washing；Colour developing: color developing agent A50 μ l is first added in every hole, adds color developing agent B50 μ l, and concussion mixes, and 37 DEG C are kept away
Light develops the color 15 minutes；Terminate: every hole adds 50 μ l of terminate liquid, terminates reaction (blue is vertical at this time turns yellow)；Measurement: with blank air-conditioning
Zero, 450nm wavelength sequentially measure the absorbance (OD value) in each hole, carry out in 15 minutes after measuring Ying Jia terminate liquid；
5) expression of real-time quantitative fluorescence PCR detection mouse ear tissue skin lesion inflammatory factor,
Total RNAs extraction: mouse ear tissue is put into 1ml Trizol, is cut with through the pretreated eye scissors of DEPC
It is broken, 200 μ l chloroforms are added in EP pipe, in being placed at room temperature for 5min after oscillation, 4 DEG C of low-temperature centrifugations: 12000rpm/min,
15min；EP pipe is taken out after centrifugation, draws upper strata aqueous phase into another EP pipe, and 500 μ l isopropanols, room temperature after concussion mixes is added
Place 10min；4 DEG C of 12000 rpm/min of low temperature are centrifuged 10min；Supernatant is abandoned, the DEPC water of 1ml pre-cooling is added in EP pipe
Diluted 75% ethyl alcohol, oscillation EP pipe, which suspends, to be precipitated；In 4 DEG C of low-temperature centrifugations: 12000rpm/min, 10min abandon supernatant, room temperature
It dries；It takes 10 μ l to dissolve without RNA enzyme water to precipitate；
RNA is quantified and reverse transcription: the RNA sample that will be dissolved in no RNA enzyme water dilutes 100 times, is read with ultraviolet specrophotometer
Absorbance value A260 and the A260/A280 ratio at 260nm wavelength is taken, the RNA concentration of sample is then calculated according to absorbance value；
The reaction system of the reverse transcription is as shown in the table:
Reaction condition: 37 DEG C, 15min is reacted, 85 DEG C, reacts 5s, 4 DEG C of preservations；
RT-PCR:
Reaction condition: 95 DEG C, 30s；95℃,5s；60 DEG C, 30s, 72 DEG C, 45s, global cycle number be 30 times, 72 DEG C,
5min；
Statistical analysis, the table of experimental data are carried out to RT-PCR experimental result using 17.0 software of SPSS in the present invention
Existing form is mean ± standard errorComparison between two groups carries out difference with Mann-Whitney t method of inspection
It analyzes, the comparison between multiple groups carries out variance analysis with One-way ANOVA method, and data have system between P < 0.05 then thinks group
Meter learns difference；The results show that the AD sample inflammation that the IAId can inhibit MC903 to induce, inhibits CD4 in corium+,Gr1+It is positive
The infiltration of cell；Inhibit the expression of inflammatory factor (IL-4, IL-5, IL-6, IL-13, TSLP)；Skin is reduced to lose through the severe edema due to hypofunction of the spleen
Degree；Mouse is inhibited to scratch behavior；Experimental result confirms that the IAId has the function of clearly anti-AD sample inflammation.
Claims (10)
1. the tryptophan metabolite indole -3-formaldehyde of structure as shown in Figure 7 treats or prevents inflammatory dermatoses in preparation
Purposes in drug or skin care item, the inflammatory dermatoses are atopic dermatitis (eczema) or psoriasis or other are inflammatory
Skin disease.
2. by purposes described in claim 1, which is characterized in that the tryptophan metabolite is selected from tryptophan metabolite
IAId, IAA or/and TrA.
3. by purposes described in claim 1, which is characterized in that the drug is the drug with immunoregulation effect.
4. by purposes described in claim 1, which is characterized in that the treatment atopic dermatitis drug is external curing idiocrasy
Dermatitis drug.
5. by purposes described in claim 1, which is characterized in that the indole -3-formaldehyde, which is used to prepare, inhibits MC903 induction
The drug of atopic dermatitis sample inflammation.
6. by purposes described in claim 1, which is characterized in that the indole -3-formaldehyde inhibits CD4 in corium+,Gr1+It is positive
The infiltration of cell；Inhibit the expression of inflammatory factor IL-4, IL-5, IL-6, IL-13, TSLP.
7. by purposes described in claim 1, which is characterized in that the indole -3-formaldehyde reduces the journey that skin is lost through the severe edema due to hypofunction of the spleen
Degree；Inhibit scratching behavior.
8. by purposes described in claim 4, which is characterized in that external application system is made in the external curing atopic dermatitis drug
Agent.
9. by purposes described in claim 4, which is characterized in that liniment or solidifying is made in the external curing atopic dermatitis drug
Glue.
10. by purposes described in claim 4, which is characterized in that the external curing atopic dermatitis drug is used to prepare into
External use skin care.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810085905 | 2018-01-29 | ||
| CN2018100859051 | 2018-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110368385A true CN110368385A (en) | 2019-10-25 |
Family
ID=68248446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910061852.4A Withdrawn CN110368385A (en) | 2018-01-29 | 2019-01-23 | Purposes of the indole -3-formaldehyde in preparation treatment atopic dermatitis drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110368385A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120252863A1 (en) * | 2009-10-23 | 2012-10-04 | Avi Dascalu | Triptans for the treatment of psoriasis |
| US20160206595A1 (en) * | 2013-08-22 | 2016-07-21 | Universita' Degli Studi Di Perugia | Indole-3-aldehyde for treating dysreactive immune disorders |
| WO2017161268A1 (en) * | 2016-03-18 | 2017-09-21 | The Texas A&M University System | Using microbiota metabolites ot differentiate naive t-cells and related methods to induce or prevent inflammatory conditions |
| US20180214399A1 (en) * | 2017-01-27 | 2018-08-02 | Temple University-Of The Commonwealth System Of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
-
2019
- 2019-01-23 CN CN201910061852.4A patent/CN110368385A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120252863A1 (en) * | 2009-10-23 | 2012-10-04 | Avi Dascalu | Triptans for the treatment of psoriasis |
| US20160206595A1 (en) * | 2013-08-22 | 2016-07-21 | Universita' Degli Studi Di Perugia | Indole-3-aldehyde for treating dysreactive immune disorders |
| WO2017161268A1 (en) * | 2016-03-18 | 2017-09-21 | The Texas A&M University System | Using microbiota metabolites ot differentiate naive t-cells and related methods to induce or prevent inflammatory conditions |
| US20180214399A1 (en) * | 2017-01-27 | 2018-08-02 | Temple University-Of The Commonwealth System Of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
Non-Patent Citations (6)
| Title |
|---|
| JINLEI YU等: "A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor", 《J ALLERGY CLIN IMMUNOL》 * |
| KERN REI CHNG等: "Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare", 《NATURE MICROBIOLOGY》 * |
| MIKITO ITO等: "Gene expression of enzymes for tryptophan degradation pathway is upregulated in the skin lesions of patients with atopic dermatitis or psoriasis", 《JOURNAL OF DERMATOLOGICAL SCIENCE》 * |
| S.H. KWON等: "A new therapeutic option for facial seborrhoeic dermatitis: indole-3-acetic acid photodynamic therapy", 《JEADV》 * |
| WEI LI等: "The Role of the Microbiome and Microbiome Derived Metabolites in Atopic Dermatitis and Non Histaminergic Itch", 《AMERICAN JOURNAL OF CLINICAL DERMATOLOGY》 * |
| 于金蕾等: "肠道菌群代谢产物IAID对特应性皮炎小鼠模型的作用", 《中国麻风皮肤病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) | |
| Takahara et al. | Berberine improved experimental chronic colitis by regulating interferon-γ-and IL-17A-producing lamina propria CD4+ T cells through AMPK activation | |
| Chamcheu et al. | Fisetin, a 3, 7, 3′, 4′-tetrahydroxyflavone inhibits the PI3K/Akt/mTOR and MAPK pathways and ameliorates psoriasis pathology in 2D and 3D organotypic human inflammatory skin models | |
| Park et al. | Comparative analysis of the microbiome across the gut–skin axis in atopic dermatitis | |
| Formiga et al. | P-cymene and rosmarinic acid ameliorate tnbs-induced intestinal inflammation upkeeping zo-1 and muc-2: Role of antioxidant system and immunomodulation | |
| Yang et al. | Lipopolysaccharide enhances FcɛRI‐mediated mast cell degranulation by increasing Ca2+ entry through store‐operated Ca2+ channels: implications for lipopolysaccharide exacerbating allergic asthma | |
| Lee et al. | Inhibitory effects of Rumex japonicus Houtt. on the development of atopic dermatitis‐like skin lesions in NC/Nga mice | |
| Xu et al. | Ginsenosides Rb1 and Rg1 protect primary cultured astrocytes against oxygen-glucose deprivation/reoxygenation-induced injury via improving mitochondrial function | |
| Nikolaidis et al. | Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection | |
| Ye et al. | Prussian blue nanozyme normalizes microenvironment to delay osteoporosis | |
| Wang et al. | Mesenchymal stem cells increase heme oxygenase 1-activated autophagy in treatment of acute liver failure | |
| Maghsoudi et al. | Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study | |
| Chen et al. | Ramulus mori (sangzhi) alkaloids alleviate high-fat diet-induced obesity and nonalcoholic fatty liver disease in mice | |
| Modderman et al. | Tartrate-resistant acid phosphatase is not an exclusive marker for mouse osteoclasts in cell culture | |
| Luo et al. | Effect of tumor suppressor PTEN gene on apoptosis and cell cycle of human airway smooth muscle cells | |
| Deng et al. | The control of clonorchiasis in Guangdong province, southern China | |
| Campolo et al. | Effect of a product containing xyloglucan and pea protein on a murine model of atopic dermatitis | |
| Kantapan et al. | Gallotannin from Bouea macrophylla seed extract suppresses cancer stem-like cells and radiosensitizes head and neck cancer | |
| Konesan et al. | The clinical trial outcomes of cranberry, D-mannose and Nsaids in the prevention or Management of Uncomplicated Urinary Tract Infections in women: a systematic review | |
| Zhang et al. | Lipopolysaccharide‐induced proliferation and glycolysis in airway smooth muscle cells via activation of Drp1 | |
| Dalouchi et al. | Human amniotic membrane mesenchymal stem cell‐conditioned medium reduces inflammatory factors and fibrosis in ovalbumin‐induced asthma in mice | |
| Shan et al. | Induction of macrophage pyroptosis-related factors by pathogenic E. coli high pathogenicity island (HPI) in Yunnan Saba pigs | |
| Urueña et al. | Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et) | |
| Meng et al. | Fetal hypoxia impacts on proliferation and differentiation of Sca-1+ cardiac progenitor cells and maturation of cardiomyocytes: a role of MicroRNA-210 | |
| Molinari et al. | Effects of a new combination of natural extracts on glaucoma-related retinal degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200611 Address after: Room 505, block r3-b, Gaoxin industrial village, No.018, Gaoxin South 7th Road, Gaoxin District, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province Applicant after: Shenzhen Zhifang Biotechnology Co., Ltd Address before: 200031 No. 12 middle Urumqi Road, Shanghai, Jingan District Applicant before: Li Wei |
|
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191025 |